Thyroid Eye Disease Market Size, Share & Trends Analysis Report By Marketed Treatment (TEPEZZA (Teprotumumab), By Pipeline Treatment (VRDN 001, VB 421, Batoclimab, Linsitnib), By Region, And By Segment Forecasts, 2025-2034

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Thyroid Eye Disease Market Snapshot Chapter 4. Global Thyroid Eye Disease Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Porter's Five Forces Analysis 4.7. Incremental Opportunity Analysis (US$ MN), 2021-2034 4.8. Global Thyroid Eye Disease Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031 4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023) 4.10. Use/impact of AI on Thyroid Eye Disease Industry Trends Chapter 5. Thyroid Eye Disease Market Segmentation 1: By Marketed Products, Estimates & Trend Analysis 5.1. Market Share By Marketed Products, 2024 & 2034 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Marketed Products: 5.2.1. TEPEZZA (Teprotumumab) Chapter 6. Thyroid Eye Disease Market Segmentation 2: By Pipeline Drugs, Estimates & Trend Analysis 6.1. Market Share by Pipeline Drugs, 2024 & 2034 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Pipeline Drugss: 6.2.1. VRDN-001 6.2.2. VB421 6.2.3. Batoclimab 6.2.4. Linsitinib Chapter 7. Thyroid Eye Disease Market Segmentation 5: Regional Estimates & Trend Analysis 7.1. Global Thyroid Eye Disease Market, Regional Snapshot 2024 & 2034 7.2. North America 7.2.1. North America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034 7.2.1.1. US 7.2.1.2. Canada 7.2.2. North America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034 7.2.3. North America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034 7.3. Europe 7.3.1. Europe Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034 7.3.1.1. Germany 7.3.1.2. U.K. 7.3.1.3. France 7.3.1.4. Italy 7.3.1.5. Spain 7.3.1.6. Rest of Europe 7.3.2. Europe Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034 7.3.3. Europe Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034 7.4. Asia Pacific 7.4.1. Asia Pacific Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034 7.4.1.1. India 7.4.1.2. China 7.4.1.3. Japan 7.4.1.4. Australia 7.4.1.5. South Korea 7.4.1.6. Hong Kong 7.4.1.7. Southeast Asia 7.4.1.8. Rest of Asia Pacific 7.4.2. Asia Pacific Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034 7.4.3. Asia Pacific Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034 7.5. Latin America 7.5.1. Latin America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034 7.5.1.1. Brazil 7.5.1.2. Mexico 7.5.1.3. Rest of Latin America 7.5.2. Latin America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034 7.5.3. Latin America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034 7.6. Middle East & Africa 7.6.1. Middle East & Africa Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034 7.6.1.1. GCC Countries 7.6.1.2. Israel 7.6.1.3. South Africa 7.6.1.4. Rest of Middle East and Africa 7.6.2. Middle East & Africa Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034 7.6.3. Middle East & Africa Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034 Chapter 8. Competitive Landscape 8.1. Major Mergers and Acquisitions/Strategic Alliances 8.2. Company Profiles 8.2.1. Horizon Therapeutics 8.2.1.1. Business Overview 8.2.1.2. Key Product/Service Offerings 8.2.1.3. Financial Performance 8.2.1.4. Geographical Presence 8.2.1.5. Recent Developments with Business Strategy 8.2.2. Viridian Therapeutics 8.2.3. Pierre Fabre/ACELYRIN 8.2.4. HanAll Biopharma/Harbour BioMed/Immunovant 8.2.5. Sling Therapeutics 8.2.6. Other Prominent Players